A J Scheen

Summary

Country: Belgium

Publications

  1. Scheen A. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics. Diabetes Metab. 2016;42:224-33 pubmed publisher
    ....
  2. Scheen A. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clin Pharmacokinet. 2017;56:703-718 pubmed publisher
    ..The additional glucose-lowering effect appears to be more marked when a gliflozin is added to a gliptin than when a gliptin is added to a gliflozin. Combining the two pharmacological options is safe and does not induce hypoglycaemia. ..
  3. Scheen A, Delanaye P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab. 2017;43:99-109 pubmed publisher
    ....
  4. request reprint
    Scheen A. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. Drugs. 2003;63:933-51 pubmed
    ..However, the best dosage of acarbose for this specific indication remains to be specified, especially when all three important parameters, efficacy, tolerance and cost, are taken into consideration. ..
  5. Scheen A, Paquot N. Gliptin versus a sulphonylurea as add-on to metformin. Lancet. 2012;380:450-2 pubmed publisher
  6. Scheen A. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Expert Opin Drug Metab Toxicol. 2013;9:363-77 pubmed publisher
    ..That being said, the durability of the glucose-lowering effect of this combination needs to be further explored in long-term controlled trials. ..
  7. Aujoulat I, Jacquemin P, Hermans M, Rietzschel E, Scheen A, Tréfois P, et al. Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium. BMC Fam Pract. 2015;16:13 pubmed publisher
    ....
  8. Scheen A. Precision medicine: The future in diabetes care?. Diabetes Res Clin Pract. 2016;117:12-21 pubmed publisher
    ..This review discusses both opportunities and challenges of precision medicine and how this new paradigm may lead to a better individualized treatment of T2D. ..
  9. Scheen A. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract. 2016;121:204-214 pubmed publisher
    ....
  10. Scheen A, Schmitt H, Jiang H, Ivanyi T. Factors associated with reaching or not reaching target HbA1c after initiation of basal or premixed insulin in patients with type 2 diabetes. Diabetes Metab. 2017;43:69-78 pubmed publisher
    ....

Detail Information

Publications16

  1. Scheen A. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics. Diabetes Metab. 2016;42:224-33 pubmed publisher
    ....
  2. Scheen A. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes. Clin Pharmacokinet. 2017;56:703-718 pubmed publisher
    ..The additional glucose-lowering effect appears to be more marked when a gliflozin is added to a gliptin than when a gliptin is added to a gliflozin. Combining the two pharmacological options is safe and does not induce hypoglycaemia. ..
  3. Scheen A, Delanaye P. Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab. 2017;43:99-109 pubmed publisher
    ....
  4. request reprint
    Scheen A. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. Drugs. 2003;63:933-51 pubmed
    ..However, the best dosage of acarbose for this specific indication remains to be specified, especially when all three important parameters, efficacy, tolerance and cost, are taken into consideration. ..
  5. Scheen A, Paquot N. Gliptin versus a sulphonylurea as add-on to metformin. Lancet. 2012;380:450-2 pubmed publisher
  6. Scheen A. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation. Expert Opin Drug Metab Toxicol. 2013;9:363-77 pubmed publisher
    ..That being said, the durability of the glucose-lowering effect of this combination needs to be further explored in long-term controlled trials. ..
  7. Aujoulat I, Jacquemin P, Hermans M, Rietzschel E, Scheen A, Tréfois P, et al. Clinical inertia in general practice, a matter of debate: a qualitative study with 114 general practitioners in Belgium. BMC Fam Pract. 2015;16:13 pubmed publisher
    ....
  8. Scheen A. Precision medicine: The future in diabetes care?. Diabetes Res Clin Pract. 2016;117:12-21 pubmed publisher
    ..This review discusses both opportunities and challenges of precision medicine and how this new paradigm may lead to a better individualized treatment of T2D. ..
  9. Scheen A. Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract. 2016;121:204-214 pubmed publisher
    ....
  10. Scheen A, Schmitt H, Jiang H, Ivanyi T. Factors associated with reaching or not reaching target HbA1c after initiation of basal or premixed insulin in patients with type 2 diabetes. Diabetes Metab. 2017;43:69-78 pubmed publisher
    ....
  11. Scheen A. GLP-1 receptor agonists and heart failure in diabetes. Diabetes Metab. 2017;43 Suppl 1:2S13-2S19 pubmed publisher
    ....
  12. Scheen A. Type 2 Diabetes and Thiazide Diuretics. Curr Diab Rep. 2018;18:6 pubmed publisher
    ..Thiazides still play a key role in the management of patients with type 2 diabetes and hypertension. ..
  13. request reprint
    Scheen A, Lefebvre P. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab Res Rev. 2000;16:114-24 pubmed
    ..However, until now, results regarding efficacy and/or safety have been disappointing or preliminary in humans...
  14. Scheen A. SGLT2 Inhibitors: Benefit/Risk Balance. Curr Diab Rep. 2016;16:92 pubmed publisher
    ..Concern about a risk of ketoacidosis and bone fractures has been recently raised, which deserves caution and further evaluation. ..
  15. Scheen A. Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract. 2017;127:224-237 pubmed publisher
    ..The clinical relevance of results with DPP-4is and GLP-1RAs is discussed. Ongoing trials with linagliptin and several once-weekly GLP-1RAs should provide new insights into remaining fundamental questions. ..
  16. Scheen A, Delanaye P. Renal outcomes with dipeptidyl peptidase-4 inhibitors. Diabetes Metab. 2017;: pubmed publisher
    ....